RecruitingNCT07156149

Fabhalta Capsules Specified Drug-use Survey

Studying C3 glomerulopathy

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Enrollment: 50 enrolled
Eligibility: 0-100 years · All sexes
Timeline: 2025 – 2028

Study locations (22)

Novartis Investigative Site, Nagoya, Aichi-ken, Japan
Novartis Investigative Site, Toyoake, Aichi-ken, Japan
Novartis Investigative Site, Chiba, Chiba, Japan
Novartis Investigative Site, Kitakyushu, Fukuoka, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Tsukuba, Ibaraki, Japan
Novartis Investigative Site, Komatsu, Ishikawa-ken, Japan
Novartis Investigative Site, Tsu, Mie-ken, Japan
Novartis Investigative Site, Nagasaki, Nagasaki, Japan
Novartis Investigative Site, Shimajiri-Gun, Okinawa, Japan
Novartis Investigative Site, Suita, Osaka, Japan
Novartis Investigative Site, Takatsuki, Osaka, Japan
Novartis Investigative Site, Kusatsu, Shiga, Japan
Novartis Investigative Site, Ohtsu, Shiga, Japan
Novartis Investigative Site, Shimotsuga Gun, Tochigi, Japan
+7 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07156149 on ClinicalTrials.gov

Other trials for C3 glomerulopathy

Additional recruiting or active studies for the same condition.

See all trials for C3 glomerulopathy →

← Back to all trials